Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
61.9%, respectively) 34 and a post-hoc analysis of this trial showed a 6069% mean 10-years relative risk reduction of T2D development 75
doi: 10.14309/ajg.0000000000001245 [PubMed] 35130044 Tokar JL, Higa JT
In the EMPA-REG study, empagliflozin significantly reduced the risk for the composite renal outcome, which included doubling of serum creatinine, progression of macroalbuminuria, initiation of renal replacement therapy, or renal death (56)
The LEADER trial provided landmark evidence that liraglutide reduces cardiovascular death and major adverse cardiovascular events in patients with type 2 diabetes
The time to therapeutic effect varies among medications, with initial glucose improvements visible within 2 weeks for both drugs
